HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3,7-dimethyl-1-propargylxanthine

potent & selective in vivo antagonist of adenosine analogs

Also Known As:

DMPX

Networked: 26 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Xanthines: 123
    - Theobromine: 130
      - 3,7-dimethyl-1-propargylxanthine: 26
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purinones: 2
        Xanthines: 123
        Theobromine: 130
        3,7-dimethyl-1-propargylxanthine: 26

Experts

1.	Altavilla, Domenica: 3 articles (01/2015 - 11/2011)
2.	Minutoli, Letteria: 3 articles (01/2015 - 11/2011)
3.	Squadrito, Francesco: 3 articles (01/2015 - 11/2011)
4.	Arena, Salvatore: 2 articles (01/2015 - 01/2012)
5.	Bitto, Alessandra: 2 articles (01/2015 - 11/2011)
6.	Irrera, Natasha: 2 articles (01/2015 - 11/2011)
7.	Magno, Carlo: 2 articles (01/2015 - 01/2012)
8.	Marini, Herbert: 2 articles (01/2015 - 11/2011)
9.	Micali, Antonio: 2 articles (01/2015 - 11/2011)
10.	Rinaldi, Mariagrazia: 2 articles (01/2015 - 11/2011)

Related Diseases

1.	Catalepsy 11/01/2001 - "Likewise, other A(2A) receptor antagonists such as (3,7-dimethyl-1-propargylxanthine) (DMPX), [E-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine] (KF 17837) and [E-1,3-diethyl-8(3,4-dimethoxystyryl-7-methyl-3,7-dihydro-1H-purine-2,6-dione] (KW 6002) antagonized catalepsy induced by haloperidol or reserpine in the rat, whereas in non-human primate models of PD, KW 6002 reduced the rigidity and improved the disability score of MPTP-treated marmosets and cynomolgus monkeys. " 06/11/1997 - "Pretreatment (i.p.) with the non-selective adenosine receptor antagonist, theophylline, or the selective adenosine A2 receptor antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX), significantly reversed haloperidol-induced catalepsy, whereas the selective adenosine A1 receptor antagonists, 8-phenyltheophylline and 8-cyclopentyl-1,3-dipropylxanthine produced no effect. "
2.	Hypotension (Low Blood Pressure) 01/01/1999 - "The vasodilation to cAMP (1-100 micromol/l), adenosine (0.01-10 micromol/l), and hypotension was significantly reduced by pretreatment with 3,7-dimethyl-1-propargylxanthine (1 micromol/l), an A2 receptor antagonist, as well as 3-isobutyl-1-methylxanthine (3 micromol/l), an inhibitor of endo- and ectophosphodiesterase, 1, 3-dipropyl-8-p-sulfophenylxanthine (100 micromol/l), an inhibitor of ecto-5'-phosphodiesterase, or alpha,beta-methylene-adenosine 5'-diphosphate (100 micromol/l), an inhibitor of ecto-5'-nucleotidase. " 01/01/1993 - "The icv and i.v. pretreatment with aminophylline, CPT and DMPX inhibited arterial hypotension and bradycardia induced by Ado, CHA and CPCA. " 06/01/1997 - "A single unilateral topical application of R-PIA (20-250 micrograms) or CHA (20-500 micrograms) produced ocular hypertension (maximum rise = 4.9 or 3.5 mmHg) within 30 min, followed by ocular hypotension (maximum fall = 2.1 or 3.6 mmHg) from 2-6 hr. The relatively selective adenosine A2 antagonist 3,7-dimethyl-1-propargylxanthine (DMPX, 320 micrograms) inhibited the early hypertension, without influencing the hypotension. "
3.	Hypoxia (Hypoxemia) 02/01/1995 - "Hypoxia (arterial PO2 = 28 +/- 1 mmHg) caused a 47 +/- 5% increase (P = 0.0008) in arteriolar diameter, 89% of which could be blocked by prior superfusion of the window space with the preferential A2-adenosine receptor antagonist 3,7-dimethyl-1-propargylxanthine (DMPX; 50 microM). " 01/01/1996 - "Adenosine deaminase (1.5 U/ml), the A1-adenosine receptor antagonist 1,3-diethyl-8-phenylxanthine (1 microM), or the A2-selective antagonist 3,7-dimethyl-1-propargylxanthine (20 microM) had no effect on anoxia-dependent glucose transport. " 10/01/1997 - "One of six, and one of five hearts from 6-hydroxydopamine treated rabbits developed ventricular fibrillation during hypoxia-reoxygenation when exposed to 3,7-dimethyl-1-propargylzanthine (DMPX) (10 µM) + adenosine (ADO) (1 µM) and DMPX (10 µM) + ADO (10 µM), respectively. "
4.	Ocular Hypotension 04/01/2004 - "In addition, the ocular hypotension induced by 2-(1-octyn-1-yl) derivative was inhibited by an adenosine A(2)-receptor antagonist 3,7-dimethyl-1-propargylxanthine, but not by an adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dipropyl xanthine. " 06/01/1997 - "A single unilateral topical application of R-PIA (20-250 micrograms) or CHA (20-500 micrograms) produced ocular hypertension (maximum rise = 4.9 or 3.5 mmHg) within 30 min, followed by ocular hypotension (maximum fall = 2.1 or 3.6 mmHg) from 2-6 hr. The relatively selective adenosine A2 antagonist 3,7-dimethyl-1-propargylxanthine (DMPX, 320 micrograms) inhibited the early hypertension, without influencing the hypotension. "
5.	Varicocele 01/01/2012 - "After the creation of experimental varicocele, rats were randomized to one of the four treatments: vehicle, PDRN, DMPX, and PDRN plus DMPX. " 01/01/2015 - "After the creation of experimental varicocele (28 days), adolescent male Sprague-Dawley rats were randomized to one of the following treatments lasting 21 days: vehicle, PDRN (8 mg/kg i.p., daily), PDRN + 3,7-dimethyl-propargylxanthine (DMPX, a specific adenosine A2A-receptor antagonist, 0.1 mg/kg i.p., daily), varicocelectomy, and varicocelectomy + PDRN (8 mg/kg i.p., daily). "

Related Drugs and Biologics

1.	Haloperidol (Haldol)
2.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
3.	Reserpine (Serpasil)
4.	istradefylline
5.	KF 17837
6.	purine
7.	methylxanthine
8.	Adenosine (Adenocard)
9.	3,7-dimethyl-1-propargylxanthine
10.	1,3-dipropyl-8-cyclopentylxanthine